What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs.
Purpose: The changes in grading of disease severity and treatment recommendations for patients with COPD in the 2017 GOLD strategy may present an opportunity for reducing treatment burden for the patients and costs to the health care system. The aim of this study was to assess the implications of the GOLD 2017 grading system in terms of change in distribution across GOLD groups A-D for existing patients in UK primary care and estimate the potential cost savings of implementing GOLD 2017 treatment recommendations in UK primary care.
Patients and methods: Using electronic health record data from the Clinical Practice Research Datalink (CPRD), patients aged >/=35 years with spirometry-confirmed COPD, receiving care during 2016, were included. The cohort was graded according to the GOLD 2017 groups (A-D), and treatment costs were calculated, according to corresponding recommendations, to observe the difference in actual vs predicted costs.
Results: When applying GOLD 2013 criteria, less than half of the cohort (46%) was assigned to GOLD A or B, as compared to 86% when applying the GOLD 2017 grading. The actual mean annual maintenance treatment cost was pound542 per patient vs a predicted pound389 for treatment according to the 2017 GOLD strategy.
Conclusion: There is a potential to make significant cost savings by implementing the grading and treatment recommendations from the 2017 GOLD strategy.
|ジャーナル名||International journal of chronic obstructive pulmonary disease|
|投稿者||Gayle, Alicia; Dickinson, Scott; Morris, Kevin; Poole, Chris; Mathioudakis, Alexander G; Vestbo, Jorgen|
|組織名||Market Access, Boehringer Ingelheim Ltd, Bracknell, UK,;email@example.com.;Medical and Scientific Affairs, Boehringer Ingelheim Ltd, Bracknell, UK.;Division of Infection, Immunity and Respiratory Medicine, University of;Manchester, Manchester, UK.;Manchester Academic Health Sciences Centre, Manchester University NHS Foundation;Trust, Manchester, UK.|